Grace Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
2analysts covering
FY EPS (est.)
-$0.74next fiscal year
Monitoring Framework
Key Performance Indicators
GTx-104 STRIVE-ON Phase 3 Hypotension Reduction Rate Annually1,900.0%Target: Statistically significant or clinically meaningful reduction in hypotension compared to oral nimodipine
Cash and Cash Equivalents Quarterly17MTarget: Sufficient capital to fund operations through NDA resubmission and pre-commercial planning
Watch Items
- FDA Type A Meeting Minutes and NDA Resubmission TimelineTrigger: Receipt of official FDA meeting minutes clarifying the path to address CMC and non-clinical deficienciesAction: Finalize and submit the updated NDA package for GTx-104
- Contract Manufacturing Organization (CMO) cGMP ComplianceTrigger: Successful resolution of cGMP deficiencies cited in the April 2026 CRLAction: Verify CMO readiness and coordinate with FDA for potential re-inspection
Research as of 19 Jun 2026